Harwars won the "2023 Qingdao Top Ten Capital Favored Enterprises"
On May 12, the 2023 Qingdao Global Venture Capital Conference, hosted by the Qingdao Municipal People's Government and under the guidance of the Asset Management Association of China, was grandly opened with the theme of "venture capital to create the era, innovation and entrepreneurship to create the future - high quality, surging new momentum". The conference released heavyweight lists such as the "2023 Qingdao Top 10 Active Venture Capital Institutions", "2023 Qingdao Top 10 Emerging Venture Capital Institutions", and "2023 Qingdao Top 10 Capital Favored Enterprises".
Harwars has been awarded the "2023 Qingdao Top 10 Capital Favorite Enterprises".
Established in September 2016, Harwars is a technology-based enterprise focused on the research and development of biological products and GCP clinical service innovation platform. It mainly engages in CRO and CDMO services, the research and development of biological products and veterinary new drugs, as well as food, agricultural products, health products, origin environment testing, safety analysis and functional evaluation, animal disease and cosmetics testing, and other businesses.
We have 12000 square meters of animal experimental facilities and have obtained qualifications such as laboratory animal use license, CMA, CNAS, GCP, etc.
The company's business continues to show steady development. With the support of the government and various sectors of society, it has completed the A+round of financing, and the post investment valuation multiple has increased, which is favored by many investors.